Figure 4
Figure 4. Effect of FX activation peptide and variants thereof on the half-life of FVII and FX. (A) Mean plasma concentration of FVII or FX antigen as a function of time after intravenous administration of 1 mg/kg FX, FVII_X, FXai, and FVII to mice. (B) Mean plasma concentration of FVII antigen as a function of time after intravenous administration of 1 mg/kg FVII_X and FVII_XHC, (C) FVII_X, FVII_X1-34 and FVII_X30-52, and (D) FVII_X, FVII_XNNAA, and FVII_XTTAA to mice. Blood was sampled in a sparse schedule as each compound was administered to a total of 6 to 9 mice, and 3 samples were taken from each animal as described in “Pharmacokinetics.”

Effect of FX activation peptide and variants thereof on the half-life of FVII and FX. (A) Mean plasma concentration of FVII or FX antigen as a function of time after intravenous administration of 1 mg/kg FX, FVII_X, FXai, and FVII to mice. (B) Mean plasma concentration of FVII antigen as a function of time after intravenous administration of 1 mg/kg FVII_X and FVII_XHC, (C) FVII_X, FVII_X1-34 and FVII_X30-52, and (D) FVII_X, FVII_XNNAA, and FVII_XTTAA to mice. Blood was sampled in a sparse schedule as each compound was administered to a total of 6 to 9 mice, and 3 samples were taken from each animal as described in “Pharmacokinetics.”

Close Modal

or Create an Account

Close Modal
Close Modal